Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications by unknown
RESEARCH Open Access
Abnormal serum microRNA profiles in
tuberous sclerosis are normalized during
treatment with everolimus: possible clinical
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Abstract
Background: Tuberous sclerosis (TSC) is a monogenic disease resulting from defects of the TSC1 or TSC2 genes,
which encode the proteins forming hamartin-tuberin tumor suppressor complex, the mammalian target of rapamycin
complex (mTOR). The mTOR pathway is constitutively activated in response to tuberin or hamartin defects. The mTOR
pathway is also regulated by a multitude of epigenetic mechanisms, one of which is regulation by microRNA (miRNA)
inhibition. This leads us to hypothesize that organ-level abnormalities of miRNA expression patterns are widespread in
TSC. The aim of the study was to evaluate the serum profiles of miRNAs in patients with TSC and subependymal giant
cell astrocytoma (SEGA) treated with mTOR inhibitor (everolimus).
Methods: Serum microRNA profiling was performed in 10 TSC-patients before and three months after everolimus
treatment, as well as in 10 sex- and age-matched healthy controls. MicroRNAs were profiled using qPCR panels (Exiqon).
Results: Of 752 tested miRNAs, 11 showed statistically significant dysregulation in patients with TSC in comparison to
controls. The following miRNAs were downregulated in TSC: miR-142-3p, miR-199a-5p, miR-142-5p and miR-136-5p;
while miR-130a-3p, miR-378a-3p, miR-130b-3p, miR-192-5p, miR-25-3p, miR-215-5p and miR-222-3p were upregulated in
TSC in comparison to the control group. After three months of everolimus treatment, mean dose 5.1 (2.6-9.7) mg/m2,
seven miRNAs reached expression levels similar to healthy controls, with miR-142-3p and miR-136 showed significant
increase over baseline levels in TSC patients. Moreover, miR-222-3p normalization due to treatment differed between
patients with mutation in TSC1 and TSC2 gene.
Conclusions: Activation of the mTOR pathway in TSC patients alters serum miRNA levels, which may be partially
reversed by an mTOR inhibitor. This indicates the involvement of miRNA dysregulation in the pathogenesis of TSC,
linking miRNA profiles with treatment efficiency.
Keywords: Tuberous sclerosis, mTOR inhibitor, everolimus,
* Correspondence: joanna.trelinska@umed.lodz.pl
†Equal contributors
1Department of Pediatrics, Oncology, Hematology and Diabetology, Medical
University of Lodz, 36/50 Sporna Str., Lodz 91-738, Poland
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Trelinska et al. Orphanet Journal of Rare Diseases  (2016) 11:129 
DOI 10.1186/s13023-016-0512-1
Background
Tuberous sclerosis (TSC) is a monogenic disease resulting
from defects of the tuberin (TSC2) or hamartin (TSC1)
genes. The TSC phenotype encompasses the abnormal
function of a range of organs and the formation of benign
tumors, predominantly in the form of renal angiomyolipo-
mas or subependymal giant cell astrocytoma (SEGA) in
the brain [1]. The treatment of TSC has been considerably
improved by the exploitation of the mTOR pathway
(mammalian target of rapamycin), which is constitutively
activated in response to tuberin or hamartin defects [2].
The mTOR signaling pathway is also regulated by a multi-
tude of epigenetic mechanisms, one of which is regulation
by microRNA (miRNA) inhibition [3–6], with miR-19 and
miR-130a/b being major regulators of mTORC activity
during early development [6], which suggests that organ-
level abnormalities of miRNA expression patterns are
widespread in TSC.
While tissue levels of miRNA expression are difficult,
if not impossible, to study in humans, circulating miRNAs
may be detected in the serum, making them applicable
biomarkers of metabolic diseases [7] and various cancers
[8]. Until now, however, no studies have been performed
on the expression profiles of microRNAs present in the
serum of patients with TSC. Therefore, the aim of the
present study was to evaluate the serum miRNA profiles
in patients with TSC before and after treatment with
mTOR inhibitor (everolimus). To investigate whether
abnormal serum profiles could be due to mTOR pathway
activation, the present study examined whether treatment
with an mTOR inhibitor (everolimus) would negate the
alterations of the miRNA profile and thus pinpoint
mTOR-dependent miRNAs in the serum.
Methods
Patients
The study group consisted of 10 children and young
adults with TSCs of different genetic backgrounds and
10 healthy, age- and sex-matched controls. The TSC
patients were described in our previous reports on re-
sponse and complications of TSC treatment [9, 10]. The
patients were recruited for the study between December
2011 and January 2014. The inclusion criteria were a
positive diagnosis of TSC and treatment with everolimus
(Votubia, Novartis, Germany). The indication for evero-
limus treatment was the presence of SEGA associated
with TSC in patients who required therapeutic interven-
tion but were not amenable to neurosurgery. From that
cohort, only patients with serum samples drawn before
the start of everolimus treatment were eligible for the
present study, which resulted in the inclusion of 10 out
of 18 individuals described in earlier reports [10].
Based on our previous experience we expected the
most pronounced clinical response to everolimus therapy
to occur within the first three months of treatment [9].
Therefore, the patients with TSC were evaluated at two
time-points – before the initiation of treatment with
everolimus and three months after its start to perform
serum miRNA profiling. Serum levels of everolimus were
monitored and titrated as described previously [10] aiming
to maintain trough concentrations of everolimus higher
than 5 ng/ml. After three months of mTOR inhibitor
treatment with a titrated dose of 5.1 (2.6-9.7) mg/m2 daily,
median everolimus serum concentration was 4.57 (1.50-
12.50) in the blood sample used for miRNA profiling.
Written informed consent was given for everolimus
treatment by the patients, or if the patient was under
16 years old, by their parent. The research was performed
in accordance with the Declaration of Helsinki and has
been approved by the Bioethics Committee of the Medical
University of Lodz (RNN/113/14/KE).
Molecular methods
For identification of TSC1 and TSC2 gene mutation,
DNA was extracted from the blood samples using a
QIAamp DNA Blood Mini Kit (Qiagen, Germany)
following the manufacturer’s instructions. DNA sam-
ples were normalized to a final 5 ng/ul. A Trusight One
sequencing kit (Illumina, San Diego, CA) was used to
perform enrichment and final analysis of TSC1 and
TSC2 genes. Each procedure was realized following the
manufacturer’s instructions. Sanger DNA sequencing
was used for validation of identified genetic variants.
Serum samples were obtained from patients with TSC
and controls using standard vials with a coagulation
activating agent (Becton-Dickinson, Franklin Lakes, NJ,
USA). After clot formation, samples were centrifuged at
2000 rpm for 20 min. Afterwards, serum was collected
into standard 0.6 ml Eppendorf vials and stored at −80 ° C
until testing. A miRCURY™ RNA Isolation Kit- Biofluids
(Exiqon, Copenhagen, Denmark) was used for miRNA
isolation, according to the manufacturer’s protocol.
Quantitative reverse transcription PCR of 752 different
miRNAs was performed using the miRCURY LNA™
Universal RT microRNA PCR kit with ExiLENT SYBR
Green according to the manufacturer’s instructions
(Exiqon). Hemolysis was assessed using the miR-451/
miR-23a ratio [11]. As a negative result was obtained
for all of the samples, profiling of the whole dataset
could proceed. Exiqon’s serum panels A and B were
used for the profiling of circulating microRNAs.
Statistical analysis
The mean expression of 56 miRNAs present in all of the
studied samples was used for normalization of miRNA
levels [12]. Only miRNA present in at least half of the
samples from either group were considered for analysis.
The formula for normalization was dCq ¼ averageCq
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N ¼ 30ð Þ  assayCq sampleð Þ . Higher dCq values thus
indicated higher expression of a given miRNA. Cq values
for specific miRNAs higher than 37 were filtered as absent
calls. Initially, expression values for pretreatment TSC and
control samples were compared using the Student’s t-test.
The Benjamini-Hochberg procedure was used to evaluate
false discovery rates (FDR). Post-treatment comparisons
were compared with expression in controls using the
Student’s t-test with Bonferroni adjustment for multiple
comparisons to control for the family-wise error rate. The
next step was to determine whether the change of any of
the miRNAs that differed with the control group would
show differences due to treatment with everolimus or mu-
tated gene (TSC1 or TSC2). To do so, a 2-way ANOVA
procedure was used, which evaluated the impact of treat-
ment, mutation and interaction of these factors. Adjusted
p values below 0.05 and (where applicable) FDR < 0.05
were considered as statistically significant.
Results
Before everolimus treatment the group of patients with
TSC did not differ from the control group in terms of
sex (6 M/4 F vs 4 M/6 F, p = 0.66) or age distribution
(11.78 ± 4.44 vs 11.80 ± 4.66 years, p = 0.99). The clinical
and genetic characteristics of patients with TSC were
presented in Table 1. Causative mutations of the TSC1
and TSC2 genes are presented in an Additional file 1:
Table S1. All 30 samples were eligible for profiling and
comparison. Out of 752 tested microRNAs commonly
detected in the human serum, 475 were detected in at
least one sample. Out of that number, 136 were present
in at least 50 % of TSC and control samples and were
deemed eligible for analysis. Overall, 27 miRNAs differed
significantly (p < 0.05) in unadjusted comparisons be-
tween TSC and control samples (Additional file 2: Table
S2). Out of those miRNAs, 11 met the FDR criterion
and were considered significant (Table 2). Raw data from
miRNA profiling was presented as Additional file 3:
Table S3. Four miRNAs were down-regulated in samples
of patients with TSC in comparison to the controls:
miR-142-3p, miR-199a-5p, miR-142-5p and miR-136-5p.
The remaining 7 miRNAs (miR-130a-3p, miR-378a-3p,
miR-130b-3p, miR-192-5p, miR-25-3p, miR-215-5p and
miR-222-3p) showed higher expression in the TSC group
Table 1 Clinical and genetic characteristics of the study group of patients with TSC
Whole group (N = 10) TSC2 (N = 5) TSC1 (N = 4) No mutation (N = 1)*
Sex (M/F) 6 / 4 2 / 3 4 / 0 1
Age (years) 11.78+/−4.44 10.32+/−5.41 13.25+/−3.61 13.17
Everolimus dose 5.95+/−2.08 6.99+/−1.77 4.56+/−2.1 6.3
Number of SEGA lesions
• 1 7/10 2/5 4/4 1
• ≥2 3/10 3/5 0 0
• bilateral 3/10 3/5 0 0
Skin lesions:
• Facial angiofibroma 9/10 5/5 3/4 1
• Fibrous cephalic plaque 3/10 2/5 0/4 1
• Hypomelanotic macules 7/10 5/5 1/4 1
• Shagreen patch 6/10 3/5 2/4 1
Other features:
• Angiomyolipomas 5/10 4/5 0/4 1
• Multiple renal cysts 0 0 0 0
• Cardiac rhabdomyoma 5/10 3/5 2/4 0
• Retinal hamartomas 4/10 3/5 0 1
• Nonrenal hamartomas 1/10 0 1/4 0
Mental retardation 7/10 5/5 1/4 1
Epilepsy 8/10 5/5 2/4 1
Number of antiepileptic drugs
• 1 1/10 0 1/4 0
• 2 4/10 3/5 0 1
• 3 3/10 2/5 1/4 0
*definite diagnosis of TSC was made according to the current clinical diagnostic criteria from The Tuberous Sclerosis Complex Diagnostic Criteria Update 2012
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than in the healthy controls. None of the miRNAs differed
significantly depending on the type (mutations of TSC1 vs
TSC2) of TSC before the initiation of treatment with
everolimus. However, the miRNA profiles of all patients
with TSC, regardless of genetic background, clustered
strongly and allowed for perfect discrimination with
healthy individuals (Fig. 1).
During three months treatment with everolimus,
significant reductions (>50 %) in SEGA volumes were
recorded in 8/10 patients, while SEGA volume did not
change in one patient and a 14.1 % increase in volume
was noted in another. There was no difference in terms
of % reduction in SEGA volume depending on the type
of mutation (TSC1 vs. TSC2).
Serum miRNA profiling performed three months
after the introduction of everolimus treatment revealed
statistically significant increases in the expression of
miR-142-3 and miR-136-5p. In the case of miR-192,
miR-130a, miR-215 (upregulated vs controls) and miR-
199a (downregulated vs controls) the difference between
pre- and post-treatment expression was not significant,
but post-treatment expression levels were significantly dif-
ferent than those noted in the control group. For the
remaining five miRNAs (miR-25, mi-378a, miR-142-5p,
miR130b and miR-222), the difference in pre- and post-
treatment expression as well as between post-treatment
expression and controls was not statistically significant
(Fig. 2a). In 10 out of the 11 differentially expressed miR-
NAs, the direction of miRNA expression change observed
after everolimus treatment did not differ significantly in
patients with mutations of TSC1 and TSC2 (Fig. 2b).
However, while the expression of miR-222 decreased to a
level similar to healthy controls in patients with mutations
of TSC1, no differences from baseline values were noted
in patients with mutations of TSC2 (Fig. 2b). No associ-
ation was found between clinical response to everolimus
treatment measured as a SEGA volume change and
miRNA levels (data not shown).
Discussion
Our results show that TSC is a disease with considerably
altered serum profile of miRNA. In addition, these
alterations seem to be mTOR-dependent, as treatment
with an mTOR inhibitor partially reversed the abnor-
malities. Furthermore, reaction to everolimus treatment
resulted in TSC-type dependent changes of miRNA
expression levels, hinting at a specific regulation of
miR-222 and its role in altering the phenotypes of
TSC1 and TSC2.
Table 2 Expression levels of miRNAs that showed significant difference between TSC and control groups. P-levels are calculated for
a comparison of the whole TSC group with controls. Results for all miRNAs evaluated by the serum panels used for the profiling















miR-142-5p −1.71 ± 0.26 −1.35 ± 0.53 −2.49 −1.65 ± 0.49 −0.52 ± 0.34 0.46 0.0000 0.0010
miR-199a-5p −2.93 ± 0.56 −2.84 ± 0.34 Undetected −2.89 ± 0.47 −1.06 ± 0.73 0.28 0.0000 0.0010
miR-142-3p 0.84 ± 0.50 0.73 ± 0.23 1.06 0.82 ± 0.38 1.78 ± 0.57 0.52 0.0003 0.0146
miR-136-5p −3.88 ± 0.85 −4.29 ± 0.51 −3.44 −3.98 ± 0.69 −2.35 ± 0.77 0.32 0.0005 0.0156
miR-130a-3p −0.71 ± 0.33 −0.57 ± 0.18 −1.88 −0.77 ± 0.46 −1.70 ± 0.53 1.90 0.0006 0.0156
miR-378a-3p −0.57 ± 0.33 −0.87 ± 0.40 0.35 −0.60 ± 0.48 −1.79 ± 0.75 2.28 0.0007 0.0157
miR-130b-3p −4.16 ± 0.48 −4.16 ± 0.22 Undetected −4.16 ± 0.38 −4.84 ± 0.32 1.60 0.0017 0.0287
miR-192-5p −2.18 ± 0.55 −2.21 ± 0.86 −2.19 −2.20 ± 0.62 −3.14 ± 0.38 1.92 0.0017 0.0287
miR-25-3p 1.25 ± 0.56 1.09 ± 0.16 0.79 1.14 ± 0.41 0.44 ± 0.49 1.63 0.0027 0.0389
miR-215-5p −3.18 ± 0.74 −3.58 ± 0.57 −3.51 −3.35 ± 0.63 −4.50 ± 0.64 2.21 0.0029 0.0389
miR-222-3p −0.43 ± 0.44 −0.09 ± 0.30 0.92 −0.16 ± 0.56 −1.27 ± 0.74 2.16 0.0031 0.0389
Fig. 1 Expression scores of the 11 miRNAs that showed significant
differences between the TSC and control groups. Higher dCq values
represent higher expression as described in the Materials and Methods
section. Expression values were normalized with one unit of the
heatmap color range corresponding to one standard deviation of
miRNA expression across the whole compared group. Gray panels
represent lack of expression of a given miRNA in a specific sample
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Fig. 2 MiRNA expression level changes before and after treatment with Everolimus. a – average levels of specific miRNAs before and after treatment
with everolimus and controls. In case of miR-136 and miR-142-3p, a significant increase in expression was observed after the introduction of therapy,
making post-treatment expression levels closer to those observed in the control group. * - significant difference between pre- and post-everolimus
expression levels and a lack of significant difference between post-everolimus and control levels, ¥ - significant difference between post-everolimus
and control expression levels with non-significant change in paired pre- vs post-treatment expression levels. b – Interaction analysis of the impact of
treatment with everolimus on miRNA expression levels. In case of mi-136 and miR-142-3p, significant increases were treatment-dependent but did not
differ between the patients with TSC1 or TSC2. In case of miR222, a decrease (in this case, a change towards values observed in the control group) was
observed only in patients with TSC1. * - significant for the pre/post treatment effect and non-significant for the treatment/TSC type interaction,
# - significant for the treatment/TSC interaction and non-significant for the pre/post treatment effect in the whole group
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The differential expression of several miRNAs in
patients with TSC was likely given the broad spectrum
of clinical features observed in these diseases. While we
are aware of phenotype variability observed in TSC pa-
tients, it was impossible to draw any conclusions from
deregulated miRNA depending on the type of mutation
or other clinical features, such as antiepileptic drug regi-
mens, due to the small size of the study group. In this
monogenic disease, the constitutively activated mTOR
signaling leads to the formation of benign tumors and
additional phenotypic traits such as seizures, intellectual
disability and developmental delay [13, 14]. MiRNAs
were shown to be associated with several clinical fea-
tures of TSC, with miR-130a and miR-130b being linked
to renal organogenesis [6]. In our study, both were
significantly upregulated in comparison to the control
group. The second-best characterized TSC-associated
miRNA was miR-142, which has already been shown to
inhibit the mTOR pathway [15]. In our dataset, levels of
miR-142 were lower in the TSC group at baseline than
in healthy controls and increased after everolimus treat-
ment. One may speculate that everolimus acts as a direct
inhibitor of mTORC1 protein complex by binding to
FKBP12 protein and alternatively, indirectly stimulating
miR-142 expression. Additionally, this reversible pattern
of TSC-associated alteration of serum miRNA profile
of miR-142 and miR-136 shows that serum levels of
microRNAs may be also used as biomarkers of treat-
ment efficiency and perhaps as predictive factors in
rare disorders, in the same way as they are used in
breast and prostate cancers [16, 17]. The fact that only
miR-142-3p reverted to control values after treatment
with everolimus may be due to its overall higher
expression, involvement of miR-142-5p in intracellular
regulatory mechanisms or differences in promoter se-
quences – further in-depth mechanistic studies would
be needed to resolve the differences between miR-142-
3p and -5p expression post-treatment.
The second notable finding of our results was the
interaction between the genetic background of TSC and
impact of everolimus treatment on serum level of miR-
222. This miRNA was previously described as being as-
sociated with the KIT/AKT pathway in gastrointestinal
stromal tumors [18] and peripheral nerve regeneration
processes [19]. While no functional studies on the
miR-222/AKT pathway associations were performed
within this work, the differential everolimus-stimulated
normalization of miR-222 expression observed in TSC1
and TSC2 patients is in line with the clinical observa-
tion that patients with TSC1 have a milder form of
disease than TSC2. Whether miR-222 plays a role in
shaping these phenotypes remains an open question.
The absence of statistical differences present in miRNA
expression profile, in TSC1 vs TSC2 mutation, or other
clinical features, before everolimus treatment may be
attributable to the limited number of patients with
variable clinical characteristics at study entry.
Our results did not indicate any dysregulation of miR-
21 reported in previous in vitro studies [20]; however, this
may be explained by a number of mechanisms. Firstly, the
cited work used a cellular model of a lymphangioleiomyo-
matosis with biallelic inactivation of TSC2, which was a
different genetic defect than the one observed in our
group. Furthermore, cellular changes of miRNA expres-
sion do not necessarily correspond to their serum levels,
as the same miRNAs may originate from different cell
types. A cellular model of miRNA expression patterns
changing under direct rapamycin stimulation may not
be thus directly translated onto serum levels. Moreover,
Trindade et al. used a 132-miRNA panel and thus may
not have picked out miRNAs present in the Exiqon
752-miR panel, which may have also contributed to the
between-study discrepancy.
Our work does have several limitations mostly linked
to the methodology of profiling and statistical power.
Firstly, no attempt was made to profile exosome-bound
miRNAs, but given that most of the miRNA present in
the blood is contained in the exosomes [21] and were
isolated during the total miRNA extraction protocol
used in our study, it is unlikely that a significant bias
could result from the analysis of free miRNA rather than
only its exosome-bound fraction. Secondly, our investi-
gation of TSC1/TSC2 differences and interactions with
treatment effects had a very low statistical power.
Single point measurement after three months of mTOR
inhibitor treatment may be considered as a limitation of
the study. However, based on our experience and previous
literature we expected the most pronounced clinical
response to everolimus therapy to occur within the first
three months of treatment [9, 22, 23]. Thus, we decided to
study the change in miRNA profile during this time.
Longer follow-ups, both clinical and molecular may be
useful for further confirmation of our report.
Despite the low number of patients, the fact that our
patients were examined before and after treatment with
mTOR inhibitors make our preliminary results a valu-
able reference for future studies on the role of miRNA
in TSC and mTOR signaling pathway abnormalities
and their functional dependencies.
Conclusions
Our results show for the first time that TSC is a disease
which considerably alters serum miRNA levels and that
changes of miR-142 and miR-136 may be reversed by
treatment with an mTOR inhibitor, making their profiles
potential indicators of treatment efficiency and hinting
at their involvement in the pathogenesis of TSC.
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Additional files
Additional file 1: Table S1. Mutations responsible for the TSC
phenotype in the study group. Reference sequences for TSC2
(NM_000548.3; NP_000539.2) and TSC1 (NM_000368.4; NP_000359.1)
were used. (DOCX 17 kb)
Additional file 2: Table S2. Univariate comparison results of miRNA
expression in patients with tuberous sclerosis (TSC) before treatment and
the control group. (XLSX 25 kb)
Additional file 3: Table S3. Raw expression data (expressed as Ct) of
the studied group. TSC - tuberous sclerosis. (XLSX 121 kb)
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